合并微血管侵犯肝癌术后TACE联合治疗的研究进展

doi:10.3877/cma.j.issn.2095-3232.2026.02.004

肝细胞癌（肝癌）是全球第六大最常诊断的癌症和第三大癌症相关死亡原因。肝切除术被认为是早期和中期肝癌的一线治疗方法。然而，术后5年复发率高达70%~80%，中位生存期仅约2年。在众多预后因素中，越来越多研究表明微血管侵犯（MVI）是导致肝癌术后复发、转移的高危因素，也是影响肝癌患者术后无复发生存期（RFS）和总生存期（OS）的独立危险因素。因此，探索有效的术后辅助治疗措施延迟复发时间及降低复发率是改善预后的关键。本文将对合并 MVI肝癌患者术后临床常见的肝动脉灌注化疗（HAIC）、靶向治疗、免疫治疗等与 TACE 联合应用进行综述，期待为临床提供参考。

关键词: 癌，肝细胞, 微血管侵犯, 经导管动脉化疗栓塞, 联合治疗

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third most cancer-related cause of death worldwide. Hepatectomy is considered as the first-line treatment for early-and middle-stage liver cancer. However, the 5-year recurrence rate is as high as 70%-80%, and the median survival time is approximately 2 years. Among multiple prognostic factors, increasing studies have shown that microvascular invasion (MVI) is a high risk factor for postoperative recurrence and metastasis of liver cancer, and it is also an independent risk factor for postoperative recurrence-free survival (RFS) and overall survival (OS) of patients with liver cancer. Therefore, it is of significance to explore effective postoperative adjuvant treatment, thereby delaying the recurrence time and lowering the recurrence rate. In this article, research progress in clinical application of hepatic arterial infusion chemotherapy (HAIC), targeted therapy, immunotherapy and common postoperative approaches combined with TACE in patients with liver cancer complicated with MVI was reviewed, aiming to provide reference for clinical practice.

Key words: Carcinoma，hepatocellular, Microvascular invasion, Transcatheter arterial chemoembolization(TACE), Combination therapy

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.DOI: 10.3322/caac.21834.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.DOI: 10.3322/caac.21660.
[3]	Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma[J]. Ann Surg, 2016, 263(6): 1112-1125.DOI: 10.1097/SLA.0000000000001556.
[4]	Xiang X, Lau WY, Wu ZY, et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study[J]. Eur J Surg Oncol, 2019, 45(8): 1460-1467.DOI: 10.1016/j.ejso.2019.03.042.
[5]	Chinnaratha MA, Chuang MA, Fraser RJL, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2016, 31(2): 294-301.DOI: 10.1111/jgh.13028.
[6]	Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J]. Ann Surg Oncol, 2016, 23(4): 1344-1351.DOI: 10.1245/s10434-015-5008-z.
[7]	刘臻玉, 武丹, 区锦玲, 等. 术后TACE对肝癌微血管侵犯治疗效果评估[J]. 肝胆胰外科杂志, 2017, 29(5): 368-372, 376.DOI: 10.11952/j.issn.1007-1954.2017.05.004.
[8]	Zhao X, Mao T, Xie Q, et al. A commentary on 'Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study'[J]. Int J Surg, 2024, 110(2): 1294-1295.DOI: 10.1097/JS9.0000000000000891.
[9]	Huang G, Lai ECH, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3): 490-505.DOI: 10.1097/SLA.0b013e318262b218.
[10]	Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: current trends and prospects[J]. Clin Mol Hepatol, 2021, 27(2): 236-245.DOI: 10.3350/cmh.2020.0204.
[11]	赵东旭, 张磊, 姜小庆, 等. HAIC是老技术还是新方法——理性看待肝动脉灌注化疗[J]. 介入放射学杂志, 2022, 31(1): 2-8.DOI: 10.3969/j.issn.1008-794X.2022.01.001.
[12]	Kelley RK, Mollon P, Blanc JF, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma[J]. Adv Ther, 2020, 37(6): 2678-2695.DOI: 10.1007/s12325-020-01378-y.
[13]	Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69.DOI: 10.1016/j.jhep.2018.02.008.
[14]	Ke Q, Wang L, Wu W, et al. Meta-analysis of postoperative adjuvant hepatic artery infusion chemotherapy versus surgical resection alone for hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 720079.DOI: 10.3389/fonc.2021.720079.
[15]	Kim DY, Ahn SH, Kim SU, et al. Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma[J]. Oncology, 2011, 81(3-4): 184-191.DOI: 10.1159/000333827.
[16]	Esagian SM, Kakos CD, Giorgakis E, et al. Adjuvant transarterial chemoembolization following curative-intent hepatectomy versus hepatectomy alone for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials[J]. Cancers, 2021, 13(12): 2984.DOI: 10.3390/cancers13122984.
[17]	Shen A, Liu M, Zheng D, et al. Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2020, 44(2): 142-154.DOI: 10.1016/j.clinre.2019.06.012.
[18]	Al Tameemi W, Dale TP, Al-Jumaily RMK, et al. Hypoxia-modified cancer cell metabolism[J]. Front Cell Dev Biol, 2019, 7: 4.DOI: 10.3389/fcell.2019.00004.
[19]	Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(3): 912-920.DOI: 10.1158/1078-0432.CCR-18-1254.
[20]	Gao S, Zhang PJ, Guo JH, et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients[J]. World J Gastroenterol, 2015, 21(36): 10443-10452.DOI: 10.3748/wjg.v21.i36.10443.
[21]	Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma[J]. Hepatology, 2008, 47(3): 929-936.DOI: 10.1002/hep.22124.
[22]	Wei X, Li N, Li S, et al. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma[J]. BMC Cancer, 2017, 17(1): 304.DOI: 10.1186/s12885-017-3293-6.
[23]	Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma[J]. JAMA Surg, 2018, 153(10): e182721.DOI: 10.1001/jamasurg.2018.2721.
[24]	Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial[J]. Ann Surg, 2018, 268(6): 943-954.DOI: 10.1097/SLA.0000000000002727.
[25]	Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines[J]. Eur J Radiol, 2018, 101: 72-81.DOI: 10.1016/j.ejrad.2018.01.025.
[26]	Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma[J]. Cancer, 2008, 112(2): 250-259.DOI: 10.1002/cncr.23175.
[27]	Wu FQ, Fang T, Yu LX, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α[J]. J Hepatol, 2016, 65(2): 314-324.DOI: 10.1016/j.jhep.2016.04.019.
[28]	Kudo M, Imanaka K, Chida N, et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14): 2117-2127.DOI: 10.1016/j.ejca.2011.05.007.
[29]	Su D. The transcatheter arterial chemoembolization combined with targeted nanoparticle delivering sorafenib system for the treatment of microvascular invasion of hepatocellular carcinoma[J]. Bioengineered, 2021, 12(2): 11124-11135.DOI: 10.1080/21655979.2021.2001239.
[30]	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.DOI: 10.1016/S0140-6736(18)30207-1.
[31]	Vogel A, Qin S, Kudo M, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(8): 649-658.DOI: 10.1016/S2468-1253(21)00110-2.
[32]	Moriyama E, Shimose S, Niizeki T, et al. Efficacy of atezolizumab plus bevacizumab-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma[J]. Curr Oncol, 2024, 31(10): 5821-5831.DOI: 10.3390/curroncol31100432.
[33]	Li H, Hu H, Cao G, et al. Prospective, multicenter study of apatinib combine with TACE in treating intermediate to advanced stage HCC patients: a real-world study from China[J]. J Clin Oncol, 2021, 39(3_suppl): 282.DOI: 10.1200/jco.2021.39.3_suppl.282.
[34]	Okusaka T, Ikeda M. Immunotherapy for hepatocellular carcinoma: current status and future perspectives[J]. ESMO Open, 2018, 3: e000455.DOI: 10.1136/esmoopen-2018-000455.
[35]	Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups[J]. Gut, 2021, 70(1): 204-214.DOI: 10.1136/gutjnl-2020-321702.
[36]	Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.DOI: 10.1016/S1470-2045(18)30351-6.
[37]	Hato T, Zhu AX, Dan G D. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma[J]. Immunotherapy, 2016, 8(3): 299-313.DOI: 10.2217/imt.15.126.
[38]	Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa[J]. Nat Rev Clin Oncol, 2018, 15(5): 310-324.DOI: 10.1038/nrclinonc.2018.9.
[39]	Zhang JX, Chen P, Liu S, et al. Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camrelizumab for treatment of unresectable hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2022, 9: 265-272.DOI: 10.2147/JHC.S358658.
[40]	Wang H, Du PC, Wu MC, et al. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion[J]. Hepatobiliary Surg Nutr, 2018, 7(6): 418-428.DOI: 10.21037/hbsn.2018.09.05.
[41]	Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv238-iv255.DOI: 10.1093/annonc/mdy308.
[42]	胡泽鑫, 李佳清, 李婉慈, 等. 经肝动脉化疗栓塞术联合靶向及免疫药物治疗中国肝癌分期Ⅱb/Ⅲa期肝细胞癌患者的有效性及安全性分析[J]. 临床肝胆病杂志, 2024, 40(3): 550-555.DOI: 10.12449/JCH240318.
[43]	彭国文, 史德刚, 王健鹏, 等. TACE联合索拉非尼及特瑞普利治疗中晚期原发性肝癌的效果[J]. 长治医学院学报, 2022, 36(5): 339-343.DOI: 10.3969/j.issn.1006-0588.2022.05.006.
[44]	Han Y, Cao G, Sun B, et al. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study[J]. BMC Gastroenterol, 2021, 21(1): 393.DOI: 10.1186/s12876-021-01967-3.
[45]	刘鹏, 解宇威, 张露旬, 等. 预防性肝动脉化疗栓塞联合抗肿瘤药物对合并微血管侵犯肝癌术后近期复发的影响[J]. 中华肝胆外科杂志, 2021, 27(9): 652-657.DOI: 10.3760/cma.j.cn113884-20201219-00628.
[46]	王礼光, 严庆, 廖珊, 等. 微血管侵犯及手术切缘对肝细胞癌患者术后生存预后的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(2): 151-157. DOI: 10.3877/cma.j.issn.2095-3232.2024.02.006.

[1]	徐一航, 彭丽婷, 林嘉谊, 曹清华, 汪跃锋, 陈丽丽, 廖冰. 结构化病理报告对肝细胞癌手术病理报告质量的影响：一项回顾性研究[J/OL]. 中华普通外科学文献(电子版), 2026, 20(01): 30-34.
[2]	方郁晖, 常钰泉, 何坤. 伴微血管侵犯的肝细胞癌术后辅助介入治疗的研究进展[J/OL]. 中华普通外科学文献(电子版), 2026, 20(01): 53-59.
[3]	梁于勇, 郑丽, 杨俭. PDCD4与原发性肝细胞癌患者肝切除术后疾病进展的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 666-669.
[4]	唐玥, 陈家璐, 覃德龙, 李宗龙, 汤朝晖, 全志伟. 基于AI的多模态影像在肝癌诊治中应用及面临挑战[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 4-9.
[5]	杨宇尘, 陈拥军. 三维可视化技术在肝癌转化治疗辅助决策中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 10-15.
[6]	刘建平, 姚灿开. 肝癌转化治疗策略选择和手术时机[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 16-20.
[7]	尹鹏飞, 吴堃, 王槐志, 蔡磊. 肝癌免疫治疗策略及其在围手术期中应用进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 21-27.
[8]	张龙, 徐伟, 孙善柯, 李文柱, 李俊达, 池涌泉, 宋进华, 王学浩, 成峰, 饶建华. 载药微球经动脉栓塞化疗在巨块型肝癌转化治疗中的疗效及安全性[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 28-35.
[9]	戴宗伯, 张城硕, 郭庭维, 何知远, 赵昊宇, 张宇慈, 张佳林. 基于MRI影像组学机器学习构建肝细胞癌微血管侵犯预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 36-44.
[10]	何泰霖, 王峻峰, 田林云, 王罡, 杨超, 王海峰. 基于CT影像组学构建肝细胞癌微血管侵犯预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 45-52.
[11]	钟文卿, 韩冰. 基于术前CT影像数据构建肝癌患者生存期Nomogram预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 53-58.
[12]	沈宏年, 陆含笑, 张硕, 姜东林, 向文, 项洁, 杨军. 非酒精性脂肪性肝病相关肝癌的临床诊治单中心分析[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 95-100.
[13]	卫姝冰, 张潇, 丁洁茹, 周晓荻, 易昕瑶, 张起帆. 同时性肝十二指肠乳头双原发癌手术治疗一例[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 114-118.
[14]	高增霞, 贺云飞, 赵娜. DCE-MRI联合Gd-EOB-DTPA MRI纹理特征对肝细胞癌经导管动脉化疗栓塞术后疗效的评估[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(02): 108-113.
[15]	王甜, 张勇, 李苗红, 刘佳玥. MRI动态增强扫描联合CT能谱成像对肝细胞癌微血管侵犯的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(01): 6-12.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Research progress in postoperative TACE combined therapy for hepatocellular carcinoma with microvascular invasion

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Research progress in postoperative TACE combined therapy for hepatocellular carcinoma with microvascular invasion